BioMarin Fights Back After NICE Blocks English Funding For £500K Batten Disease Drug

 
• By Neena Brizmohun
  
NICE said BioMarin's asking price for its Batten disease treatment was too high for routine use. (Shutterstock)

More from Health Technology Assessment

More from Market Access